Hydrochloric Acid

Hydrochloric Acid

SCHEMBL967604

CCCCC(P)(CCCC)CCCC.Cl

nearest known ligand 0.38

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
ESR1 known ✓ P03372 1/20 0.31
ESR2 known ✓ Q92731 1/20 0.31
TSHR P16473 3/20 0.38
LMNA P02545 1/20 0.38
THRB P10828 1/20 0.35
FDPS P14324 1/20 0.33
DNM1 Q05193 3/20 0.32
ALDH1A1 P00352 1/20 0.30
TDP1 Q9NUW8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL27823791 0.97 TSHR (0.35) TSHRLMNATHRBFDPSDNM1
Hydrochloric Acid SCHEMBL27366251 0.97 TSHR (0.35) TSHRLMNATHRBFDPSDNM1
Hydrochloric Acid SCHEMBL27490900 0.97 TSHR (0.35) TSHRLMNATHRBFDPSDNM1
SCHEMBL93520 0.97 TSHR (0.40) TSHRLMNATHRBFDPSESR1
Hydrochloric Acid SCHEMBL2529722 0.94 TSHR (0.39) TSHRTHRBFDPSDNM1
Hydrochloric Acid SCHEMBL28458733 0.94 TSHR (0.39) TSHRTHRBFDPSDNM1
Hydrochloric Acid SCHEMBL11521329 0.94 TSHR (0.33) TSHRLMNATHRBFDPS
Bromide SCHEMBL3390282 0.93 TSHR (0.38) TSHRLMNATHRBFDPSDNM1
Water SCHEMBL553356 0.93 TSHR (0.38) TSHRLMNATHRBFDPSESR1
Iodide SCHEMBL553390 0.93 TSHR (0.38) TSHRLMNATHRBFDPSESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11549134-B2 Modified amadoriase and method for producing the same, agent for improving surfactant resistance of amadoriase and composition for measuring HbA1c using the same KIKKOMAN CORPORATION (JP) 2023-01-10 US claimed
US-20220064524-A1 STABILIZED PEROVSKITE QUANTUM DOT MATERIAL QUANTUM ADVANCED SOLUTIONS LIMITED (GB) 2022-03-03 US claimed
US-20200263228-A1 MODIFIED AMADORIASE AND METHOD FOR PRODUCING THE SAME, AGENT FOR IMPROVING SURFACTANT RESISTANCE OF AMADORIASE AND COMPOSITION FOR MEASURING HbA1c USING THE SAME KIKKOMAN CORPORATION (JP) 2020-08-20 US claimed
US-20160186232-A1 MODIFIED AMADORIASE AND METHOD FOR PRODUCING THE SAME, AGENT FOR IMPROVING SURFACTANT RESISTANCE OF AMADORIASE AND COMPOSITION FOR MEASURING HbA1c USING THE SAME KIKKOMAN CORPORATION (JP) 2016-06-30 US claimed
EP-3031914-A1 MODIFIED AMADORIASE AND METHOD FOR PRODUCING SAME, AGENT FOR IMPROVING SURFACTANT-RESISTANCE OF AMADORIASE AND COMPOSITION FOR MEASURING HbA1c USING SAME Kikkoman Corporation (JP) 2016-06-15 EP claimed
US-20050130228-A1 Dosing form for a polymer support, use of said dosing form in organic chemical synthesis and method for production of said dosing form H. LUNDBECK A/S (DK) 2005-06-16 US claimed
US-20030138847-A1 Dosing form for a polymer support, use of said dosing form in organic chemical synthesis and method for production of said dosing form H. LUNDBECK A/S (DK) 2003-07-24 US claimed
EP-1268050-A2 DOSING FORM FOR A POLYMER SUPPORT, USE OF SAID DOSING FORM IN ORGANIC CHEMICAL SYNTHESIS AND METHOD FOR PRODUCTION OF SAID DOSING FORM H. Lundbeck A/S (DK) 2003-01-02 EP claimed
WO-2001068598-A2 DOSING FORM FOR A POLYMER SUPPORT, USE OF SAID DOSING FORM IN ORGANIC CHEMICAL SYNTHESIS AND METHOD FOR PRODUCTION OF SAID DOSING FORM H. LUNDBECK A/S (DK) 2001-09-20 WO claimed
EP-0451596-B1 Phosphonylation process ALBRIGHT & WILSON (GB) 1995-07-19 EP claimed
EP-0451596-A1 Phosphonylation process ALBRIGHT & WILSON LIMITED (GB) 1991-10-16 EP claimed
US-4831166-A REACTING ALKYLENE OXIDE WITH ACYLACETATE USING IONIC HALIDE CATALYST BASF AKTIENGESELLSCHAFT (DE) 1989-05-16 US claimed
US-3971817-A DISPROPORTIONATION OF DIMETHYL-TIN DICHLORIDE AND TIN TETRACHLORIDE CIBA-GEIGY CORPORATION (US) 1976-07-27 US claimed
US-20260022412-A1 METHOD AND KIT FOR DETECTING MICROORGANISM OR CELL, DETECTING MICROORGANISM RELATED SUBSTANCE OR CELL RELATED SUBSTANCE KIKKOMAN CORPORATION (JP) 2026-01-22 US disclosed
US-12344784-B2 Stabilized perovskite quantum dot material QUANTUM ADVANCED SOLUTIONS LIMITED (GB) 2025-07-01 US disclosed
WO-2025121285-A1 PHOSPHINE-PALLADIUM COMPLEX, POLYMERIZATION CATALYST, AND METHOD FOR PRODUCING AROMATIC POLYMER 日本化学工業株式会社 2025-06-12 WO disclosed
EP-0139404-A1 Biocidal water treatment Albright & Wilson Limited (GB) 1985-05-02 EP disclosed
US-4266071-A Process for the preparation of N-(1-alkoxycarbonylethyl)-2,6-dialkylanilines CIBA-GEIGY CORPORATION (US) 1981-05-05 US disclosed
US-4260782-A Process for the preparation of N-(1'-alkoxycarbonylethyl)-2,6-dialkylanilines CIBA-GEIGY CORPORATION (US) 1981-04-07 US disclosed
US-3971817-A DISPROPORTIONATION OF DIMETHYL-TIN DICHLORIDE AND TIN TETRACHLORIDE CIBA-GEIGY CORPORATION (US) 1976-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260022412-A1 METHOD AND KIT FOR DETECTING MICROORGANISM OR CELL, DETECTING MICROORGANISM RELATED SUBSTANCE OR CELL RELATED SUBSTANCE P2RY6, TK1, P2RX6 ESR1 3830/4885ESR2 4042/4885TSHR 2654/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.